Two different docetaxel resistant MCF-7 sublines exhibited different gene expression pattern

Molecular Biology Reports

Volumn 39, Issue 4, 2012, Pages 3505-3516

  İşeri, Özlem Darcansoy ^a,b   Kars, Meltem Demirel ^a,c   Gündüz, Ufuk ^a  

^a MIDDLE EAST TECHNICAL UNIVERSITY   (Turkey)

^b BASKENT UNIVERSITY   (Turkey)

^c SELCUK UNIVERSITY   (Turkey)

Author keywords

CDNA microarray; Docetaxel; MCF 7; Multidrug resistance

Indexed keywords

APRIL PROTEIN; CYTOKINE; DOCETAXEL; GROWTH FACTOR; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE; ISOPROTEIN; TAXOID; TUMOR PROTEIN;

ARTICLE; BREAST CARCINOMA; CANCER RESISTANCE; CELL PROLIFERATION; CELL STRAIN MCF 7; DNA MICROARRAY; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; PROTEIN METABOLISM; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; BREAST TUMOR; DRUG EFFECT; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; STATISTICS; TUMOR CELL LINE; TUMOR GENE;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; HUMANS; NEOPLASM PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEIN ISOFORMS; STATISTICS AS TOPIC; TAXOIDS;

EID: 84862989279     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-011-1123-5     Document Type: Article

References (64)

1. Nogales E, Wolf SH, Downing K (1998) Structure of the ab tubulin dimer by electron crystallography. Nature 391:199-203
2. Clemons M, Leahy M, Valle J, Jayson G, Ranson M, Howell A (1997) Clinical oncology update. Review of recent trials of chemotherapy for advanced breast cancer: The taxanes. Eur J Cancer 33:2183-2193
3. Kumar N (1981) Taxol-induced polymerization of purified tubulin. Mechanism of action. J Biol Chem 256:10435-10441
4. Makarovskiy AN, Siryaporn E, Hixson DC, Akerley W (2002) Survival of docetaxel-resistant prostate cancer cells in vitro depends on phenotype alterations and continuity of drug exposure. Cell Mol Life Sci 59:1198-1211
5. Sanfilippo O, Ronchi E, De Marco C, Di Fronzo G, Silvestrini R (1991) Expression of P-glycoprotein in breast cancer tissue and in vitro resistance to doxorubicin and vincristine. Eur J Cancer 27: 155-158
6. Dalton WS (1997) Mechanisms of drug resistance in hematologic malignancies. Semin Hematol 34:3-8
7. Young AM, Allen CE, Audus KL (2003) Efflux transporters of the human placenta. Adv Drug Deliv Rev 55:125-132
8. Işeri OD, Kars MD, Arpaci F, Gündüz U (2010) Gene expression analysis of drug-resistant MCF-7 cells: Implications for relation to extracellular matrix proteins. Cancer Chemother Pharmacol 65(3):447-455
9. Işeri OD, Kars MD, Gunduz U (2010) Drug resistant MCF-7 cells have altered expression levels of β-tubulin isotypes and mutations in TUBB gene. Int J Hematol Oncol 20(2):75-83
10. Kars MD, Işeri OD, Gündüz U (2010) Drug resistant breast cancer cells overexpress ETS1 gene. Biomed Pharmacother 64(7):458-462
11. Kars MD, Iseri OD, Gunduz U, Ural AU, Arpaci F, Molnar J (2006) Development of rational in vitro models for drug resistance in breast cancer and modulation of MDR by selected compounds. Anticancer Res 26:4559-4568
12. Işeri ÖD, Kars MD, Eroǧlu S, Gündüz U (2009) Cross-resistance development and combined applications of anticancer agents in drug resistant MCF-7 cell lines. Int J Hematol Oncol 1(19):1-8
13. Kars MD, Iseri ÖD, Ural AU, Avcu F, Beyzadeoglu M, Dirican B, Gündüz U (2009) Development of radioresistance in drug resistant human MCF-7 breast cancer cells. J Radiother Pract 8:207-213
14. Cobley JG, Clark AC, Weerasurya S, Queseda FA, Xiao JY, Bandrapali N, D'Silva I, Thounaojam M, Oda JF, Sumiyoshi T, Chu MH (2002) CpeR is an activator required for expression of the phycoerythrin operon (cpeBA) in the cyanobacterium Fremyella diplosiphon and is encoded in the phycoerythrin linkerpolypeptide operon (cpeCDESTR). Mol Microbiol 44:1517-1531
15. Kars G, Gündüz U, Yücel M, Türker L, Eroglu I (2006) Hydrogen production and transcriptional analysis of nifD, nifK and hupS genes in Rhodobacter sphaeroides O.U.001 grown in media with different concentrations of molybdenum and iron. Int J Hydrogen Energy 31:1536-1544
16. Yabuki N, Sakata K, Yamasaki T, Terashima H, Mio T, Miyazaki Y, Fujii T, Kitada FK (2007) Gene amplification and expression in lung cancer cells with acquired paclitaxel resistance. Cancer Genet Cytogenet 173:1-9
17. Andreadis C, Gimotty PA, Wahl P, Hammond R, Houldsworth J, Schuster SJ, Rebbeck TR (2007) Members of the glutathione and ABC-transporter families are associated with clinical outcome in patients with diffuse large B-cell lymphoma. Blood 109(8): 3409-3416
18. Martinez VG, Williams KJ, Stratford IJ, Clynes M, O'Connor R (2008) Overexpression of cytochrome P450 NADPH reductase sensitises MDA 231 breast carcinoma cells to 5-fluorouracil: Possible mechanisms involved. Toxicol In Vitro 22(3):582-588
19. Reijntjes S, Rodaway A, Maden M (2007) The retinoic acid metabolising gene, CYP26B1, patterns the cartilaginous cranial neural crest in zebrafish. Int J Dev Biol 51:351-360
20. Wu Q, Dawson MI, Zheng Y, Hobbs PD, Agadir A, Jong L, Li Y, Liu R, Lin B, Zhang XK (1997) Inhibition of trans-retinoic acidresistant human breast cancer cell growth by retinoid X receptorselective retinoids. Mol Cell Biol 17:6598-6608
21. Kutuzovaa GD, DeLuca HF (2007) 1,25-Dihydroxyvitamin D3 regulates genes responsible for detoxification in intestine. Toxicol Appl Pharmacol 218(1):37-44
22. Rochat B, Morsman JM, Murray GI, Figg WD, McLeod HL (2001) Human CYP1B1 an anticancer agent metabolism: Mechanism for tumor-specific drug inactivation? J Pharmacol Exp Ther 296:537-541
23. Bournique B, Lemarie A (2002) Docetaxel (Taxotere) is not metabolized by recombinant human CYP1B1 in vitro, but acts as an effector of this isozyme. Drug Metab Dispos 30:1149-1152
24. Martinez VG, O'Connor R, Liang Y, Clynes M (2008) CYP1B1 expression is induced by docetaxel: Effect on cell viability and drug resistance. Br J Cancer 98(3):564-570
25. Angus WGR, Larsen MC, Jefcoate CR (1999) Expression of CYP1A1 and CYP1B1 depends on cell-specific factors in human breast cancer cell lines: Role of estrogen receptor status. Carcinogenesis 20(6):947-955
26. Sanlioglu AD, Dirice E, Aydin C, Erin N, Koksoy S, Sanlioglu S (2005) Surface TRAIL decoy receptor-4 expression is correlated with TRAIL resistance in MCF7 breast cancer cells. BMC Cancer 5:54
27. Pitti RM, Marsters SA, Lawrence DA, Roy M, Kischkel FC, Dowd P, Huang A, Donahue CJ, Sherwood SW, Baldwin DT, Godowski PJ, Wood WI, Gurney AL, Hillan KJ, Cohen RL, Goddard AD, Botstein D, Ashkenazi A (1998) Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 396:699-703
28. Mild G, Bachmann F, Boulay JL, Glatz K, Laffer U, Lowy A, Metzger U, Reuter J, Terracciano L, Herrmann R, Rochlitz C (2002) DCR3 locus is a predictive marker for 5-fluorouracilbased adjuvant chemotherapy in colorectal cancer. Int J Cancer 102(3):254-257
29. Takahama Y, Yamada Y, Emoto K, Fujimoto H, Takayama T, Ueno M, Uchida H, Hirao S, Mizuno T, Nakajima Y (2002) The prognostic significance of overexpression of the decoy receptor for Fas ligand (DcR3) in patients with gastric carcinomas. Gastric Cancer 5(2):61-68
30. Stumm S, Meyer A, Lindner M, Bastert G, Wallwiener D, Guckel B (2004) Paclitaxel treatment of breast cancer cell lines modulates Fas/Fas ligand expression and induces apoptosis which can be inhibited through the CD40 receptor. Oncology 66:101-111
31. Ishimura N, IsomotoH,Bronk SF,Gores GJ(2006) Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells. Am J Physiol Gastrointest Liver Physiol 290(1):G129-G136
32. Secchiero P, Gonelli A, Carnevale E, Corallini F, Rizzardi C, Zacchigna S, Melato M, Zauli G (2004) Evidence for a proangiogenic activity of TNF-related apoptosis-inducing ligand. Neoplasia 6(4):364-373
33. Secchiero P, Gonelli A, Carnevale E, Milani D, Pandolfi A, Zella D, Zauli G (2003) TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways. Circulation 107(17):2250-2256
34. Hahne M, Kataoka T, Schröter M, Hofmann K, Irmler M, Bodmer JL, Schneider P, Bornand T, Holler N, French LE, Sordat B, Rimoldi D, Tschopp J (1998) APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med 188(6):1185-1190
35. Kern C, Cornuel JF, Billard C, Tang R, Rouillard D, Stenou V, Defrance T, Ajchenbaum-Cymbalista F, Simonin PY, Feldblum S, Kolb JP (2004) Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway. Blood 103(2):679-688
36. Nakatani K, Thompson DA, Barthel A, Sakaue H, Liu W, Weigel RJ, Roth RA (1999) Up-regulation of Akt3 in estrogen receptordeficient breast cancers and androgen-independent prostate cancer lines. J Biol Chem 274(31):21528-21532
37. Faridi J, Wang L, Endemann G, Roth RA (2003) Expression of constitutively active Akt-3 in MCF-7 breast cancer cells reverses the estrogen and tamoxifen responsivity of these cells in vivo. Clin Cancer Res 9(8):2933-2939
38. Teixeira C, Reed JC, Pratt MA (1995) Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res 55(17):3902-3907
39. Tang SC, Beck J, Murphy S, Chernenko G, Robb D, Watson P, Khalifa M (2004) BAG-1 expression correlates with Bcl-2, p53, differentiation, estrogen and progesterone receptors in invasive breast carcinoma. Breast Cancer Res Treat 84(3):203-213
40. Doong H, Vrailas A, Kohn EC (2002) What's in the 'BAG'?-a functional domain analysis of the BAG-family proteins. Cancer Lett 188(1-2):25-32
41. Takayama S, Sato T, Krajewski S, Kochel K, Irie S, Millan JA, Reed JC (1995) Cloning and functional analysis of BAG-1: A novel Bcl-2-binding protein with anti-cell death activity. Cell 80(2):279-284
42. Lee JH, Takahashi T, Yasuhara N, Inazawa J, Kamada S, Tsujimoto Y (1999) Bis, a Bcl-2-binding protein that synergizes with Bcl-2 in preventing cell death. Oncogene 18(46):6183-6190
43. Brimmell M, Burns JS, Munson P, McDonald L, O'Hare MJ, Lakhani SR, Packham G (1999) High level expression of differentially localized BAG-1 isoforms in some oestrogen receptorpositive human breast cancers. Br J Cancer 81(6):1042-1051
44. Nozawa H, Tadakuma T, Ono T, Sato M, Hiroi S, Masumoto K, Sato Y (2006) Small interfering RNA targeting epidermal growth factor receptor enhances chemosensitivity to cisplatin, 5-fluorouracil and docetaxel in head and neck squamous cell carcinoma. Cancer Sci 97(10):1115-1124
45. Ciardiello F, Caputo R, Borriello G, Del Bufalo D, Biroccio A, Zupi G, Bianco AR, Tortora G (2002) ZD1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells. Int J Cancer 98(3):49-463
46. Duncan MR, Frazier KS, Abramson S, Williams S, Klapper H, Huang X, Grotendorst GR (1999) Connective tissue growth factor mediates transforming growth factor beta-induced collagen synthesis: Down-regulation by cAMP. FASEB J 13(13):1774-1786
47. Wahab N, Cox D, Witherden A, Mason RM (2007) Connective tissue growth factor (CTGF) promotes activated mesangial cell survival via up-regulation of mitogen-activated protein kinase phosphatase-1 (MKP-1). Biochem J 406(1):131-138
48. Xie D, Nakachi K, Wang H, Elashoff R, Koeffler HP (2001) Elevated levels of connective tissue growth factor, WISP-1, and CYR61 in primary breast cancers associated with more advanced features. Cancer Res 61(24):8917-8923
49. Kubo M, Kikuchi K, Nashiro K, Kakinuma T, Hayashi N, Nanko H, Tamaki K (1998) Expression of fibrogenic cytokines in desmoplastic malignant melanoma. Br J Dermatol 139(2):192-197
50. Wenger C, Ellenrieder V, Alber B, Lacher U, Menke A, Hameister H, Wilda M, Iwamura T, Beger HG, Adler G, Gress TM (1999) Expression and differential regulation of connective tissue growth factor in pancreatic cancer cells. Oncogene 18(4): 1073-1080
51. Kitazono M, Takebayashi Y, Ishitsuka K, Takao S, Tani A, Furukawa T, Miyadera K, Yamada Y, Aikou T, Akiyama S (1998) Prevention of hypoxia-induced apoptosis by the angiogenic factor thymidine phosphorylase. Biochem Biophys Res Commun 253(3):797-803
52. Hosotani Y, Kashiwamura S, Kimura-Shimmyo A, Sekiyama A, Ueda H, Ikeda T, Mimura O, Okamura H (2008) Interleukin-18 prevents apoptosis via PI3K/Akt pathway in normal human keratinocytes. J Dermatol 35(8):514-524
53. Bernard-Marty C, Treilleux I, Dumontet C, Cardoso F, Fellous A, Gancberg D, Bissery MC, Paesmans M, Larsimont D, Piccart MJ, Di Leo A (2002) Microtubule-associated parameters as predictive markers of docetaxel activity in advanced breast cancer patients: Results of a pilot study. Clin Breast Cancer 3:341-345
54. Banerjee A, Roach MC, Trcka P, Luduena RF (1990) Increased microtubule assembly in bovine brain tubulin lacking the type III isotype of beta-tubulin. J Biol Chem 265:1794-1799
55. Bhattacharya R, Cabral F (2004) A ubiquitous b-tubulin distrupts microtubule assembly and inhibits cell proliferation. Mol Biol Cell 15:3123-3131
56. Bloom GS, Luca FC, Vallee RB (1985) Microtubule-associated protein 1B: Identification of a major component of the neuronal cytoskeleton. Proc Natl Acad Sci USA 82(16):5404-5408
57. Black MM, Slaughter T, Fischer I (1994) Microtubule-associated protein 1b (MAP1b) is concentrated in the distal region of growing axons. J Neurosci 14(2):857-870
58. Evans DB, Rank KB, Bhattacharya K, Thomsen DR, Gurney ME, Sharma SK (2000) Tau phosphorylation at serine 396 and serine 404 by human recombinant tau protein kinase II inhibits tau's ability to promote microtubule assembly. J Biol Chem 275(32): 24977-24983
59. Li QQ, Wang WJ, Xu JD, Cao XX, Chen Q, Yang JM, Xu ZD (2007) Up-regulation of CD147 and matrix metalloproteinase-2,-9 induced by P-glycoprotein substrates in multidrug resistant breast cancer cells. Cancer Sci 98(11):1767-1774
60. Weinstein RS, Jakate SM, Dominguez JM, Lebovitz MD, Koukoulis GK, Kuszak JR et al (1991) Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. Cancer Res 51(10):2720-2726
61. Fischer OM, Hart S, Gschwind A, Prenzel N, Ullrich A (2004) Oxidative and osmotic stress signaling in tumor cells is mediated by ADAM proteases and heparin-binding epidermal growth factor. Mol Cell Biol 24(12):5172-5183
62. Thompson EW, Newgreen DF, Tarin D (2005) Carcinoma invasion and metastasis: A role for epithelial-mesenchymal transition? Cancer Res 65(14):5991-5995
63. Voulgari A, Pintzas A (2009) Epithelial-mesenchymal transition in cancer metastasis: Mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim Biophys Acta 1796(2):75-90
64. Işeri ÖD, Kars MD, Arpaci F, Atalay C, Pak I, Gündüz U (2011) Drug resistant MCF-7 cells exhibit epithelial-mesenchymal related gene expression pattern. Biomed Pharmacother 65(1):40-45